Mycophenolate mofetil 200 mg in 1 mL Oral Suspension
RxNorm 311880
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 311880 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: mycophenolate mofetil 200 mg in 1 mL Oral Suspension.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Mycophenolate mofetil 200 mg/ML Oral Suspension
(Atom ID: 1442128)
PSNPrescribable
Prescribable Name (PSN):
Mycophenolate mofetil 200 mg in 1 mL Oral Suspension
(Atom ID: 8705242)
SYPrescribable
Synonym (SY):
Mycophenolate mofetil 200 mg per 1 mL Oral Suspension
(Atom ID: 8705241)
PTPrescribable
Designated preferred name (PT):
Mycophenolate mofetil 200 mg/mL oral suspension
(Atom ID: 11437703)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely mycophenolate mofetil 200 mg/1 mL conventional release oral suspension (clinical drug)
(Atom ID: 11440363)
Patient Education
Mycophenolate
Mycophenolate (CellCept) is used with other medications to help prevent transplant organ rejection (attack of the transplanted organ by the immune system of the person receiving the organ) in adults who have received heart and liver transplants and in adults and children 3 months of age and older who have received kidney transplants. Mycophenolate (Myfortic) is used with other medications to help prevent the body from rejecting kidney transplants. Mycophenolate is in a class of medications called immunosuppressive agents. It works by weakening the body's immune system so it will not attack and reject the transplanted organ.
[Learn More]
* Please review the disclaimer below.